Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma’s Ilumya expansion bid gets USFDA nod for review
Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for treating adults with active psoriatic arthritis. This marks a crucial step for Sun Pharma in expanding its medicine portfolio. The US regulator has accepted the application for review.
Stocks to Watch for March 17: Reliance Industries, Sun Pharma, Tata Motors CV, RVNL and more
From Tata Motors planning to increase the prices of its commercial vehicle range by up to 1.5% to GMDC signing a memorandum of understanding with NMDC Ltd, here are some stocks to watch ahead of Tuesday trading session.
Sun Pharma’s ILUMYA gets US FDA review nod for psoriatic arthritis use
The pharma firm added that ILUMYA has received marketing authorisation from more than 55 health authorities worldwide since its original approval, including in India, Japan, the European Union, China, Australia and Canada.
Sun Pharma Share Price Highlights: Sun Pharma Stock Price History
Sigma Advanced System exits non-core pharma investment
With sale of entire stake held in Extrovis AG for a consideration of Rs 137.61 crore
Sun Pharma Share Price Live Updates: Weekly Returns for Sun Pharma
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunity
Saion Mukherjee, Managing Director & Head of Equity Research at Nomura says Indian pharmaceutical companies are preparing to tap the opportunity as semaglutide goes off patent. While several large firms such as Sun Pharma, Lupin and Zydus could benefit from the growing diabetes and obesity drug market, Mukherjee highlighted Dr Reddy’s as his top pick in the sector. He said the opportunity will play out across domestic and global markets, with semaglutide likely to become an important growth driver for Indian pharma companies in the coming years.
Sensex nosedives 1,342 pts; Nifty sinks below 23,900 level; VIX jumps 11.41%
Nifty ended below the 23,900 level. Auto, private bank and financial services shares declined, while pharma, oil & gas shares and healthcare shares advanced.
Sun Pharma up 5% in 1 week, nears 52-week high; what's driving this stock?
Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.
CCL Products, Sai Life Sciences on Mayuresh Joshi’s watchlist for earnings strength
Mayuresh Joshi, Director of Research at Marketsmith India, is watching earnings-resilient sectors such as consumer discretionary, banking, and pharmaceuticals as market remains volatile. Along with CCL Products and Sai Life Sciences, Strides Pharma Science and ICICI Bank are on his watchlist, while Vishal Mega Mart remains a domestic consumption play worth tracking.
IT stocks may bounce back; pharma growth outlook strong: Elara Securities
Bino Pathiparampil, Head of Research at Elara Securities, says HUL’s recovery depends on the execution of its strategy to tap new-age consumption trends as traditional FMCG growth remains muted. He sees near-term rebound potential in IT stocks after sharp corrections, though AI-led growth may take time to emerge. He adds semaglutide could create a $1 billion opportunity in India’s pharma market over the next four years.
